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Optimizing photodynamic therapy: in vivo pharmacokinetics of
liposomal meta-(tetrahydroxyphenyl)chlorin in feline squamous
cell carcinoma
Abstract
PURPOSE: The aim of the present study was to optimize and simplify photodynamic therapy using a
new liposomal formulation of the photosensitizer meta-(tetrahydroxyphenyl)chlorin [m-THPC (Foscan);
liposomal m-THPC (Fospeg)] and to reduce systemic reactions to the photosensitizer.
EXPERIMENTAL DESIGN: To examine the pharmacokinetics of liposomal m-THPC, we determined
tissue and plasma variables in feline patients with spontaneous squamous cell carcinoma. In vivo
fluorescence intensity measurements of tumor and skin were done with a fiber spectrophotometer after
i.v. injection of m-THPC or liposomal m-THPC in 10 cats. Blood samples, drawn at several time points
after photosensitizer administration, were analyzed by high-performance liquid chromatography.
RESULTS: None of the liposomal m-THPC-treated cats showed side effects during or after drug
injection. Fluorescence intensities, fluorescence ratios (tumor fluorescence divided by skin
fluorescence), and bioavailability in the tumor were 2 to 4 times higher with liposomal m-THPC
compared with m-THPC. Liposomal m-THPC concentration in the tumor increased constantly to reach a
maximum at 4 hours after injection. Plasma concentration and bioavailability were approximately 3
times higher with liposomal m-THPC compared with m-THPC measured at the time points of highest
plasma concentration. The distribution half-life was shorter with liposomal m-THPC, resulting in
maximal tumor accumulation up to 5.5 times earlier. Maximal tumor accumulation and maximal
fluorescence ratio with liposomal m-THPC occurred at the same time point, indicating maximal
selectivity. In both groups, all cats responded to therapy. CONCLUSIONS: Liposomal m-THPC was
well tolerated by all cats and seems to have superior pharmacokinetic properties compared with
m-THPC. The efficacy of the drug warrants further study.
Optimizing Photodynamic Therapy: In vivo Pharmacokinetics of
Liposomalmeta-(Tetrahydroxyphenyl)Chlorin in Feline
Squamous Cell Carcinoma
Julia Buchholz,1,3 Barbara Kaser-Hotz,1Tania Khan,3 Carla Rohrer Bley,1Katja Melzer,1
Reto A. Schwendener,4 Malgorzata Roos,2 and Heinrich Walt3
Abstract Purpose:The aim of the present study was to optimize and simplify photodynamic therapy
using a new liposomal formulation of the photosensitizer meta-(tetrahydroxyphenyl)chlorin
[m-THPC (Foscan); liposomal m-THPC (Fospeg)] and to reduce systemic reactions to the
photosensitizer.
Experimental Design:To examine the pharmacokinetics of liposomalm-THPC, we determined
tissue and plasma variables in feline patients with spontaneous squamous cell carcinoma. In vivo
fluorescence intensity measurements of tumor and skin were done with a fiber spectrophoto-
meter after i.v. injection of m-THPC or liposomal m-THPC in 10 cats. Blood samples, drawn at
several time points after photosensitizer administration, were analyzed by high-performance
liquid chromatography.
Results: None of the liposomal m-THPC ^ treated cats showed side effects during or after
drug injection. Fluorescence intensities, fluorescence ratios (tumor fluorescence divided by
skin fluorescence), and bioavailability in the tumor were 2 to 4 times higher with liposomal
m-THPC compared with m-THPC. Liposomal m-THPC concentration in the tumor increased
constantly to reach a maximum at 4 hours after injection. Plasma concentration and bioavail-
ability were f3 times higher with liposomal m-THPC compared with m-THPC measured at
the time points of highest plasma concentration. The distribution half-life was shorter with
liposomal m-THPC, resulting in maximal tumor accumulation up to 5.5 times earlier. Maximal
tumor accumulation and maximal fluorescence ratio with liposomal m-THPC occurred at the
same time point, indicating maximal selectivity. In both groups, all cats responded to therapy.
Conclusions: Liposomalm-THPCwaswell toleratedbyall cats and seems tohave superiorphar-
macokinetic properties comparedwithm-THPC.The efficacy of the drugwarrants further study.
The first reports on photodynamic therapy (PDT) date back to
the beginning of the last century, when researchers observed
that a combination of light with hematoporphyrin induces cell
death (1). In 1995, the U.S. Food and Drug Administration
approved PDT as a novel form of therapy against cancer, and
since then, PDT has been used more frequently.
PDT includes two components combined to induce cellular
and tissue effects in an oxygen-dependent manner. The first is a
‘‘light-sensitive’’ substance called the photosensitizer. The
second is light of a specific wavelength (laser light) to
maximally activate the tumor-localized photosensitizer. On
activation, a photosensitizer undergoes type I (electron or
hydrogen transfer) or type II (local generation of cytotoxic
singlet oxygen) photochemical reactions.
Tumor destruction associated with PDT involves three
principal mechanisms (2): (a) direct tumor cell kill (3), (b)
destruction of tumor-associated vasculature (4–6), and (c)
activation of an immune response against tumor cells (7, 8). A
short drug-light interval allows the photosensitizer to accu-
mulate predominantly in the vascular compartment. PDT-
mediated vascular effects range from transient vascular spasm,
vascular stasis, and thrombus formation to total permanent
vessel occlusion and can include enhanced vascular leakiness
(5). A longer drug-light interval results in maximal concentra-
tion of the photosensitizer in the tumor, causing direct tumor
cell destruction. This was shown recently for the second-
generation photosensitizer meta-(tetrahydroxyphenyl)chlorin
[m-THPC (Foscan)] and indicates that the in vivo effects occur
via an indirect vascular effect as well as a more direct effect at
different drug-light intervals (9, 10).
To optimize PDT, liposomes are presently being tested as
carrier and delivery systems with the aim of improving the
tumoritropic behavior of photosensitizers.
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The present study was thus designed to optimize PDT in
cat patients with spontaneous cutaneous squamous cell
carcinomas using a new, liposomal formulation of m-THPC
[liposomal m-THPC (Fospeg)]. Pet animals with spontane-
ously developing cancer provide an excellent opportunity to
study many aspects of cancer from etiology to treatment.
Squamous cell carcinomas are common neoplasms in cats.
Similar to human cutaneous squamous cell carcinoma, there
is an etiologic correlation between development of the
neoplasm and exposure to UV light (11). Several studies
have shown the efficacy of PDT in the treatment of feline
squamous cell carcinoma (12–15).
The aim of the present study was to investigate the
accumulation of liposomal m-THPC in tumor and skin in situ
with a spectrophotometer and to define the plasma pharma-
cokinetics in cats. We hypothesized that, with liposomal
m-THPC, a higher tumor-to-skin ratio and an earlier m-THPC
concentration peak in plasma and neoplastic tissue could be
achieved.
Patients andMaterials andMethods
Animal patients. Ten pet cats with histologically confirmed
cutaneous squamous cell carcinoma were included in the study.
Tumors were clinically staged using a modification of the WHO system
(14) and included thoracic radiographs, blood analysis (hematology
and organ variables), regional lymph node aspiration, and urinalysis.
All animal treatments were conducted according to the approval
issued by the official veterinary authorities of the Canton of Zurich.
All animal owners signed a written informed consent.
Photosensitizers. The original lipophilic formulation of m-THPC
(1.5 mg/mL, 3 mL vials) and the new liposomal formulation of m-THPC
(1.5 mg/mL, 3 mL vials) were used (kindly provided by Biolitec AG,
Jena, Germany). m-THPC is practically insoluble in all aqueous media.
The single component is of >99% purity, with its fluorescence emis-
sion peak in the red at 652 nm. The molecular weight of m-THPC is
680.24 Da.
Liposomal m-THPC basically comprises dipalmitoylphosphatidyl-
choline, dipalmitoylphosphatidylglycerol, and pegylated distearoyl-
phosphatidylethanolamine as liposome-forming compounds. The
physical stability of the liposomal formulation was assessed by
monitoring the particle size distribution using photon correlation
spectroscopy. The mean particle size was f140 nm. The degree of
pegylation was 2.5% to 5% and the degree of m-THPC was 10%.
The drug is associated with the lipid membrane of the unilamellar
liposomes. The liposomal m-THPC formulation can be diluted with
aqueous medium or biological fluids without precipitation.
Drug application. All animals received 0.15 mg m-THPC/kg body
weight out of the same production lot of either m-THPC or lipo-
somal m-THPC. The drug was continuously injected into a cephalic
or femoral vein over 10 minutes. Cats that were given m-THPC were
premedicated with Clemastin (Tavegyl, Novartis Consumer Health
Schweiz AG, Bern, Switzerland; 0.05 mg/kg), a H1 receptor anti-
histamine. Cats receiving liposomal m-THPC were not premedicated
to observe systemic reactions, if any.
For all measurements, time t = 0 corresponded to the end of the
injection.
Spectrophotometric fluorescence measurements. In vivo fluorescence
measurements were done noninvasively (a) in normal skin (unpig-
mented) and (b) in the tumor every hour for the first 10 hours and then
at 16, 24, 36 (m-THPC group only), 48, and 72 hours after drug
injection. A fiber spectrometer (optical biopsy system, kindly provided
by Dr. Martin O’Dwyer, Department of Physics and Astronomy,
University of Glasgow, Glasgow, United Kingdom and Biolitec) was
used. This instrument is composed of a 405 nm laser diode excitation
source, an optical fiber, and a spectrometer. Emission from the tissue
was collected, and after suitable filtering, the spectra from 450 to
700 nm were displayed (integration time 500 ms). Intensity values at
652 nm were recorded. Photobleaching at the surface was not relevant
due to short acquisition times and a low power at the end of the fiber
(30 AW). The tip of the fiber was held perpendicular to the surface of
the tissue exerting constant pressure to assure contact. At each location,
three individual measurements were obtained and the mean value
was determined. The spectrophotometer was calibrated at zero (dark
current) before each measurement.
Photosensitizer concentration in plasma/urine. To determine the
plasma concentration of m-THPC, blood samples were obtained
1, 3, 6, 8, 16, 24, 48, and 72 hours after application of the photo-
sensitizer.
The 1 to 1.5 mL blood samples were collected in sterile CTAD tubes
(Becton Dickinson AG, Basel, Switzerland). The tubes were immediately
centrifuged for 30 minutes at 2,500  g and 4jC. The plasma
supernatant was stored at 80jC. The plasma m-THPC concentration
was measured by high-performance liquid chromatography (Biolitec). A
weighed sample of 20 mg was blended with 1.5 mL DMSO/methanol
(5:3, v/v) and agitated for 12 hours at 60jC. Afterward, the samples
were centrifuged for 5 minutes at 13,000  g and the clear supernatant
(1 mL) was removed for high-performance liquid chromatography
analysis [Gold System Module 168, Beckman + fluorescence detector
RF-10A XL, Shimadzu (Duisburg, Germany); column, ‘‘LiChroCART
250-4’’ with Purospher STAR RP-18 end capped, 5 Am, Merck
(Darmstadt, Germany); guard column, ‘‘LiChroCART 4-4’’ with Pur-
ospher STAR RP-18e, 5 Am, Merck; temperature, 30jC; mobile phase,
acetonitrile/H2O + 0.1% trifluoroacetic acid = 57.5% (v/v)/42.5% (v/v);
flow rate, 1 mL/min]. The fluorescence wavelength was set at 410 nm for
excitation and 653 nm for emission. The plasma m-THPC concentration
was calculated from a calibration curve constructed by plotting the peak
height values of m-THPC standard solutions versus their concentrations.
Urine samples were taken at different time points after injection and
analyzed by high-performance liquid chromatography for potential
m-THPC content.
Treatment. PDT of the spontaneous cutaneous carcinomas in
client-owned cats was done under anesthesia 48 hours after m-THPC
injection and 16 hours after liposomal m-THPC injection. The interval
of 48 hours for m-THPC was based on previous experience in cats (12).
For liposomal m-THPC, the shorter interval of 16 hours was based on
results from laboratory mice, which indicated a more rapid metabolism
for the liposomal formulation.5
A 652 nm diode laser (Applied Optronics Corp., South Plainfield,
NJ) was used as light source. The light was delivered using a quartz
optical fiber with a microlens at the tip (Medlight SA, Ecublens,
Switzerland). Noncontact surface illumination of the entire tumor area
plus a security margin of 5 mm was implemented. The power at the
end of the fiber was measured by a calibrated power meter at 652 nm
and the laser was adjusted to obtain a 0.05 W/cm2 nonthermal power
density on the irradiated surfaces. A dose of 10 J/cm2 was delivered and
the treatment time (200 seconds) was controlled with the laser’s built
in countdown timer.
Anesthesia was induced by i.v. application of Buprenorphine
(Temgesic, Essex Chemie AG, Luzern, Switzerland; 10 Ag/kg), Mid-
azolam (Dormicum, Roche Pharma AG, Reinach, Switzerland; 0.2 mg/
kg iv), and Propofol (Propofol, Fresenius Kabi AG, Stans, Switzerland).
Propofol was given until tracheal intubation was possible. Anesthesia
was maintained with Isoflurane (Forene, Abbott AG, Baar, Switzerland;
1-3% in oxygen). Hemoglobin oxygen saturation and heart rate were
monitored continuously throughout anesthesia with a pulse oxymeter,
and values were recorded before and during illumination. Ringer’s
lactate solution was administered i.v. at 4 mL/kg/h.
5 Dr. Susanna Gra« fe, unpublished data.
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Posttreatment, the cats received Buprenorphine (10 Ag/kg) every
8 hours for 48 hours. The following 3 weeks they received Piroxicam
(Pirocam, Spirig Pharma AG, Egerkingen, Switzerland; 0.3 mg/cat) once
daily as pain medication. If necessary, amoxicillin and clavulanic acid
(Synulox, Pfizer AG, Zurich, Switzerland; 12.5 mg/kg twice daily) were
given.
Toxicity. Acute toxicity was assessed during and after photosensitizer
administration. Blood and urine samples were taken 72 hours after
injection of the photosensitizer to rule out an effect of the drug on
organ variables. Tissue reactions were assessed during, 1 hour after,
and 4 days after light treatment. Toxicity was scored according to
Common Terminology Criteria for Adverse Events version 3.0.
Statistical analysis. Pharmacokinetic values were obtained by using
pharmacokinetic functions for Microsoft Excel. Description of data is
given by mean and median F SD. StatView 5.0.1 software was used
for statistical analysis. Data were investigated graphically by box plots.
To investigate differences between both drugs with respect to tissue
fluorescence and plasma variables, the Mann-Whitney U test was
applied. Ps < 0.05 were considered significant.
Results
Animal patients. All patients included in the study were
European short hair cats. Four of the patients were female
spayed and six were male neutered. There was no statistically
significant difference concerning gender, age, or weight
between the two groups. All tumors (n = 10) were classified
as squamous cell carcinoma by histopathologic examination.
All tumors were located on the head, with the majority of
tumors occurring on the nasal planum (n = 6). Most of the
treated squamous cell carcinomas were low-stage tumors
(T1a-T2a; n = 7). None of the cats had evidence of metastatic
disease (N0M0).
Spectrophotometric fluorescence measurements. Patients
receiving m-THPC showed mean and median maximal tumor
fluorescence intensities of 160.88 and 154.89 (relative units),
respectively. These maxima were seen between 36 and 48 hours
after injection (Table 1). In patients treated with liposomal
m-THPC, the mean and median maximal m-THPC fluorescence
intensities in the tumor were 275.67 and 279.00 (relative
units), respectively. In this group, maxima were reached 5 to
10 hours after injection (Table 1). The fluorescence intensity
maxima were not significantly different (P = 0.139), although a
distinct difference is obvious (Fig. 1). The intensity increased
rapidly over the first 4 hours to reach a maximum and a plateau
phase 4 to 6 hours after liposomal m-THPC injection. The time
point of intensity maxima differed significantly (P = 0.015)
between the two groups. The fluorescence ratio, defined as the
mean fluorescence intensity of the tumor divided by the mean
fluorescence intensity of normal skin at a given time point, was
calculated for each individual animal. For m-THPC, these ratios
ranged from 1.79 to 4.81 (mean and median values of 3.02 and
2.45, respectively). For liposomal m-THPC, the ratios ranged
from 3.47 to 18.34 (mean and median values of 10.75 and
11.98, respectively). The fluorescence ratio was higher for
liposomal m-THPC compared with m-THPC (Fig. 1), although
statistical significance was not achieved (P = 0.053). Highest
ratios were reached much later after injection of m-THPC than
after injection of liposomal m-THPC (Table 1); with liposomal
m-THPC, a rapid increase during the first 5 to 10 hours could
be observed. For liposomal m-THPC only, the time point of the
maximal fluorescence intensities and the time point of the
highest tumor-to-skin ratio were identical.
The mean and median bioavailability in the tumor,
calculated for the first 16 hours after injection [area under the
curve (AUC)], was significantly higher for liposomal m-THPC
than for m-THPC (P = 0.030; Fig. 2). The bioavailability in the
skin was similar for both photosensitizers (P = 0.305). The
AUC16 ratio, calculated from the tumor values divided by the
skin values, for m-THPC resulted in mean and median values of




















1 78.72 36 1.79 4 334.41 232.59 1.44
2 249.03 36 4.81 6 1,081.73 359.29 3.01
3 154.89 48 2.45 24 900.73 582.00 1.55
Mean 160.88 40.00 3.02 11.33 772.29 391.29 2.00
Median 154.89 36.00 2.45 6.00 900.73 359.29 1.55
SD 85.31 6.93 1.59 11.02 389.87 176.89 0.88
4 279.00 6 18.34 6 3,559.33 391.33 9
5 407.33 10 11.98 10 4,332.50 420.50 10.30
6 234.67 10 7.82 10 1,989.00 478.33 4.16
7 212.00 7 3.95 7 2,244.17 1,188.50 1.89
8 99.33 7 3.47 7 4,332.50 420.50 10.30
9 350.67 5 13.66 5 2,428.50 376.50 6.45
10 346.67 6 16.00 6 2,781.50 427.72 6.50
Mean 275.67 7.29 10.75 7.29 3,095.38 529.05 6.94
Median 279.00 7.00 11.98 7.00 2,781.50 420.50 6.50
SD 103.96 1.98 5.82 1.98 980.48 292.55 3.18
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2.00 and 1.55, whereas the AUC16 ratio for liposomal m-THPC
showed mean and median values of 6.94 and 6.50, respectively
(P = 0.053; Table 1).
Photosensitizer concentration in plasma/urine. In the m-
THPC group, mean and median maximal m-THPC levels of
431.38 and 458.81 ng/mL plasma were reached during the
first 8 hours after injection. During this time range, m-THPC
levels remained constant or increased slightly. Afterward, the
photosensitizer concentration decreased to reach a level near
baseline 48 hours after injection. For m-THPC, the calcu-
lated distribution half-life (hour 0-16) resulted in mean and
median values of 46.74 and 44.62 hours, respectively. The
calculated elimination half-life (hour 16-72) showed mean
and median values of 20.64 and 20.32 hours, respectively
(Table 2). In the liposomal m-THPC group, significantly
higher mean and median maximal m-THPC levels were found
(1,317.08 and 1,523.30 ng/mL plasma, respectively) compared
with the m-THPC group (P = 0.017). The highest m-THPC
plasma levels were seen at the first time point measured
followed by an immediate and rapid disappearance of the
photosensitizer signal (Fig. 3). For liposomal m-THPC, the
calculated distribution half-life (hour 0-16) was significantly
shorter (P = 0.017), resulting in mean and median values
of 9.36 and 7.95 hours. The calculated elimination half-life
(hour 16-72) resulted in mean and median values of 22.90
and 19.83 hours, which were comparable with the values
obtained with m-THPC (P = 0.732; Table 2). Plasma drug
concentrations returned to near baseline 48 hours after
injection.
The mean and median bioavailability, calculated at 16 and
72 hours, was much lower in the m-THPC group compared
with the liposomal m-THPC group (P = 0.053 and 0.087,
respectively; Table 2). m-THPC could not be detected in the
urine at any of the time points examined after injection.
Treatment response. All three cats in the m-THPC group had
a complete response to therapy. No tumor recurrence could be
observed thus far. In the liposomal m-THPC group, four cats
had a complete response and three had a partial response. Two
of these three cats had tumor recurrences and no further
therapy was done, whereas one cat was retreated with PDT and
then had a complete response. No tumors have recurred in the
cats with a complete response. The longest follow-up time in
both therapy groups, however, is only 380 days.
Toxicity. During or shortly after m-THPC injection, two of
the three cats showed side effects, such as tachypnoe, salivation,
and excitation, although they were premedicated.
The liposomal m-THPC injection was well tolerated by all
cats. None of the liposomal m-THPC–treated animals showed
signs of acute toxicity, such as vomiting, diarrhea, salivation,
tachypnoe, excitation, or death. There was no obvious
difference in skin reaction between the two groups. Only one
cat in the liposomal m-THPC group (patient 7), which had
extremely high skin fluorescence intensities, developed sun-
burn-like reactions on the face f10 days after injection, which
healed uneventfully.
Fig. 2. Bioavailability of eitherm-THPC (=1) or liposomalm-THPC (=2) in the
tumor during the first16 hours after injection: box plot investigation.
Fig. 1. Tumor and skin fluorescence intensities as a
function of time after injection of eitherm-THPC
or liposomalm-THPC. Points, median values of all
patients; bars, SD.
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Discussion
PDT has the potential to be a powerful treatment modality
for cancer either applied solitary or in combination with
chemotherapy (16), surgery (17), radiotherapy (18), or other
strategies, such as hyperthermia (19). However, low selectivity,
inconveniently long drug-light intervals, and prolonged gener-
alized photosensitivity are problems encountered with this
therapy modality. Modifying the photosensitizing moiety
through its physicochemical properties may improve PDT.
In the present study, a new formulation of a commercially
available photosensitizer has been studied to address the
following hypotheses: the liposomal formulation (a) allows a
shorter drug-light interval, (b) results in a higher tumor-to-skin
ratio, and (c) shows an earlier plasma peak compared with the
conventional formulation.






















1 458.81 8 56.86 20.32 0.01 0.03 4,974.64 7,765.53
2 238.12 6 44.62 23.25 0.02 0.03 3,390.01 7,039.13
3 597.22 6 38.75 18.35 0.02 0.04 8,217.56 19,193.93
Mean 431.38 6.67 46.74 20.64 0.02 0.03 5,527.40 11,332.86
Median 458.81 6.00 44.62 20.32 0.02 0.03 4,974.64 7,765.53
SD 181.12 1.15 9.24 2.47 0.00 0.00 2,460.79 6,817.56
4 1,690.10 0 6.97 22.35 0.10 0.03 13,341.84 22,050.53
5 854.92 0 6.45 17.71 0.11 0.04 5,975.30 9,418.44
6 693.74 0 9.61 14.36 0.07 0.05 6,591.53 11,190.45
7 1,757.00 0 6.37 19.83 0.11 0.03 11,294.70 17,921.64
8 1,523.30 0 14.42 44.66 0.05 0.02 17,593.76 39,756.32
9 1,789.45 0 7.95 13.55 0.09 0.05 13,736.35 26,490.77
10 911.04 0 13.72 27.82 0.05 0.02 10,671.77 22,260.78
Mean 1,317.08 0 9.36 22.90 0.08 0.03 11,315.03 21,298.42
Median 1,523.30 0 7.95 19.83 0.09 0.03 11,294.70 22,050.53
SD 477.03 0 3.41 10.76 0.03 0.01 4,095.35 10,196.85
*Maximal plasma concentration.
cTime point of maximal plasma concentration.
bDistributionhalf-life.
xEliminationhalf-life.
Fig. 3. Plasmam-THPC concentration as a function
of time after injection of eitherm-THPC or liposomal
m-THPC. Points, median values of all patients;
bars, SD.
Cancer Therapy: Preclinical
www.aacrjournals.orgClin Cancer Res 2005;11(20) October15, 2005 7542
Maximal tumor fluorescence intensities with liposomal
m-THPC were nearly twice as high compared with m-THPC.
This is important clinically, as the drug dose needed could
probably be lowered. A lower drug dose would result in a
shorter generalized photosensitivity of the patients. With
liposomal m-THPC, the time of maximal fluorescence intensity
in the tumor was shown to be significantly earlier than with
m-THPC (P = 0.015). These results suggest that the drug-light
interval could be reduced by a factor of 5.5, representing a
second relevant advantage for clinics and fulfilling the first
hypothesis. For liposomal m-THPC, the time point of maximal
tumor accumulation was in accordance with the time of
maximal tumor to skin ratio. For m-THPC, this was not the case
in the present study. In previously published work using
m-THPC, a drug-light interval of 4 to 12 hours resulted in
extensive skin and muscle necrosis (20, 21), indicating a low
tumor-to-normal tissue ratio at this early time point. In
contrary, no obvious changes in normal tissues were observed
at any drug-light interval when pegylated m-THPC was used
(22). Results of our study clearly show much higher tumor-to-
skin ratios in spontaneous feline squamous cell carcinoma with
the liposomal drug. In general, the uptake of pegylated
photosensitizers is enhanced due to an increased vascular
permeability of tumor vessels. In addition, tumor tissue lacks a
functional lymphatic system; therefore, extravasated macro-
molecules cannot return efficiently to the central circulation. By
showing a 4 times higher maximal tumor-to-skin ratio for
liposomal m-THPC compared with m-THPC, we have proven
our second hypothesis. A mean fluorescence ratio of f12
indicates a distinct selectivity of the new formulation. The lack
of statistical significance may be due to the fairly small sample
size in each group, although a clear trend was seen (P = 0.053).
The results reported here point at differences of 3 to 4 orders
of magnitude for liposomal m-THPC compared with m-THPC
in terms of changes in AUC, which means a significantly higher
bioavailability for the new liposomal m-THPC formulation
(P = 0.030). This suggests again the possibility to decrease the
typical administered dosage of m-THPC. In addition, the
AUC16 ratio for liposomal m-THPC is f4 times higher than
for m-THPC, showing a much higher overall accumulation in
the tumor than in the skin.
For liposomal m-THPC, the maximal plasma m-THPC levels
were f3.5 times higher than for m-THPC (P = 0.017). With
liposomal m-THPC, the maximum plasma concentration was
attained at the first time point measured, whereas for m-THPC
maximum plasma concentrations were seen f6 hours after
injection. For the lipophilic m-THPC, a delayed concentration
maximum has been shown in the plasma of humans, dogs, cats,
rabbits, and nude rats (23). Reasons for this phenomenon, such
as aggregation of hydrophobic substances (e.g., m-THPC), can
be substantially decreased by using liposomal formulations.
Therefore, our third hypothesis of an earlier plasma peak after
liposomal m-THPC injection was confirmed. The mean half-
lives calculated for m-THPC as well as the shape of the graphs
are similar to those of a previous study in cats (24). The shorter
distribution half-life of liposomal m-THPC could be the reason
for the earlier maximal photosensitizer accumulation in the
tumor.
We did not see any complication during injection of liposo-
mal m-THPC. During and after the injection of m-THPC, two of
three cats showed side effects, such as tachypnoe, salivation, and
excitation. Premedication was used because, in previously
treated cats, these symptoms were seen at our institution. These
side effects led to the discontinuation of m-THPC after 3 cats.
Cats in the liposomal m-THPC group were not premedicated
because this could have masked even weak side effects. The
owners were told to keep the cats away from direct sunlight for
another 10 days. The one cat that developed pronounced skin
reactions was, in addition to a very low tumor-to-skin AUC16,
housed at high altitude and went outside 1 week after injection.
In this study, we examined tumor, skin, and plasma drug
levels to generate an optimized and simplified PDT protocol. In
a recent report (10), no significant correlation between tumor
drug level and PDT response was found, but correlation
between plasma drug level and tumor response was found for
m-THPC-PDT. This suggests that illumination in clinical PDT
should be done at highest plasma levels, targeting the
vasculature more than the tumor cell directly. In another study,
m-THPC-PDT had two peaks of activity: an early effect on
tumor vasculature synchronous to the plasma peak level fol-
lowed by a late direct effect at maximum tumor accumulation
(9). After having determined the tumor and tissue peaks in the
feline species, our next step will be to compare the PDT out-
come of the cats treated to date with cats treated optimally (i.e.,
at the time of highest liposomal m-THPC tumor accumulation
versus cats treated at the time of the plasma peak).
All patients of both groups responded to the treatment
showing either a complete or a partial tumor remission.
Due to the small patient number and the fact that we just now
determined the tumor and plasma peaks for liposomal m-THPC
in the feline species, a true comparison between the effectiveness
of the two formulations is not yet possible. Liposomal m-THPC
seems to be at least as effective as m-THPC.
In conclusion, we have shown that the new, liposomal
formulation of m-THPC is a safe drug, causing no noticeable
acute side effects in any cat in the present study. With liposomal
m-THPC, important progress for PDT could be achieved. The
combination of a higher selectivity and significantly earlier
tumor and plasma peaks will result in a more efficient and
eventually more effective PDT protocol.
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